The antiplatelet activity of magnolol is mediated by PPAR-β/γ

Biochemical Pharmacology

Volumn 84, Issue 6, 2012, Pages 793-803

  Shih, Ching Yu ^a   Chou, Tz Chong ^a  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

Author keywords

Cyclic GMP; Magnolol; Nitric oxide; Peroxisome proliferator activated receptors (PPARs); Platelet aggregation; Protein kinase C

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; ARACHIDONIC ACID; CALCIUM ION; COLLAGEN TYPE 1; CYCLIC GMP; CYCLIC GMP DEPENDENT PROTEIN KINASE; CYCLOOXYGENASE 1; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GSK 0660; GUANYLATE CYCLASE; HORMONE RECEPTOR BLOCKING AGENT; LACTATE DEHYDROGENASE; MAGNOLOL; NITRIC OXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN KINASE B; PROTEIN KINASE C ALPHA; THROMBOXANE B2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLEEDING TIME; CALCIUM MOBILIZATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG RECEPTOR BINDING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; MAGNOLIA OFFICINALIS; MEDICINAL PLANT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN PROTEIN INTERACTION; RECEPTOR BLOCKING; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS; UPREGULATION;

ANIMALS; BIPHENYL COMPOUNDS; BLOOD PLATELETS; CALCIUM; CYCLIC GMP; CYCLIC GMP-DEPENDENT PROTEIN KINASES; CYCLOOXYGENASE 1; FIBRINOLYTIC AGENTS; GUANYLATE CYCLASE; LIGNANS; MICE; MICE, INBRED ICR; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; PHOSPHORYLATION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PPAR GAMMA; PPAR-BETA; PROTEIN KINASE C-ALPHA; PROTO-ONCOGENE PROTEINS C-AKT; RABBITS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SIGNAL TRANSDUCTION; THROMBOXANE B2; UP-REGULATION;

EID: 84864942152     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2012.06.022     Document Type: Article

References (31)

1. T. Smith, G. Dhunnoo, I. Mohan, and V. Charlton-Menys A pilot study showing an association between platelet hyperactivity and the severity of peripheral arterial disease Platelets 18 2007 245 248
2. K.T. Tan, and G.Y. Lip The potential role of platelet microparticles in atherosclerosis Thromb Haemost 94 2005 488 492
3. S. Willoughby, A. Holmes, and J. Loscalzo Platelets and cardiovascular disease Eur J Cardiovasc Nurs 1 2002 273 288
4. L.K. Jennings Mechanisms of platelet activation: need for new strategies to protect against platelet-mediated atherothrombosis Thromb Haemost 102 2009 248 257
5. A. Yessoufou, and W. Wahli Multifaceted roles of peroxisome proliferator-activated receptors (PPARs) at the cellular and whole organism levels Swiss Med Wkly 140 2010 w13071
6. R.A. Hegele, and Retinoid X receptor heterodimers in the metabolic syndrome N Engl J Med 353 2005 604 615
7. C. Blanquart, O. Barbier, J.C. Fruchart, B. Staels, and C. Glineur Peroxisome proliferator-activated receptors: regulation of transcriptional activities and roles in inflammation J Steroid Biochem Mol Biol 85 2003 267 273
8. M. Hamblin, L. Chang, Y. Fan, J. Zhang, and Y.E. Chen PPARs and the cardiovascular system Antioxid Redox Signal 11 2009 1415 1452
9. F.Y. Ali, S.J. Davidson, L.A. Moraes, S.L. Traves, M. Paul-Clark, and D. Bishop-Bailey Role of nuclear receptor signaling in platelets: antithrombotic effects of PPARbeta FASEB J 20 2006 326 328
10. F.Y. Ali, P.C. Armstrong, A.R. Dhanji, A.T. Tucker, M.J. Paul-Clark, and J.A. Mitchell Antiplatelet actions of statins and fibrates are mediated by PPARs Arterioscler Thromb Vasc Biol 29 2009 706 711
11. T.C. Chou, C.Y. Shih, and Y.T. Chen Inhibitory effect of alpha-lipoic acid on platelet aggregation is mediated by PPARs J Agric Food Chem 59 2011 3050 3059
12. Y.J. Lee, Y.M. Lee, C.K. Lee, J.K. Jung, S.B. Han, and J.T. Hong Therapeutic applications of compounds in the Magnolia family Pharmacol Ther 130 2011 157 176
13. C.M. Teng, C.C. Chen, F.N. Ko, L.G. Lee, T.F. Huang, and Y.P. Chen Two antiplatelet agents from Magnolia officinalis Thromb Res 50 1988 757 765
14. S.S. Choi, B.Y. Cha, Y.S. Lee, T. Yonezawa, T. Teruya, and K. Nagai Magnolol enhances adipocyte differentiation and glucose uptake in 3T3-L1 cells Life Sci 84 2009 908 914
15. T.C. Chou, Y.F. Lin, W.C. Wu, and K.M. Chu Enhanced nitric oxide and cyclic GMP formation plays a role in the anti-platelet activity of simvastatin Br J Pharmacol 153 2008 1281 1287
16. H.L. Kuo, J.C. Lien, C.H. Chung, C.H. Chang, S.C. Lo, and I.C. Tsai NP-184[2-(5-methyl-2-furyl) benzimidazole], a novel orally active antithrombotic agent with dual antiplatelet and anticoagulant activities Naunyn Schmiedebergs Arch Pharmacol 381 2010 495 505
17. T.C. Chou, C.Y. Li, M.H. Yen, and Y.A. Ding Antiplatelet effect of amlodipine: a possible mechanism through a nitric oxide-mediated process Biochem Pharmacol 58 1999 1657 1663
18. M. Emerson, S. Momi, W. Paul, P.F. Alberti, C. Page, and P. Gresele Endogenous nitric oxide acts as a natural antithrombotic agent in vivo by inhibiting platelet aggregation in the pulmonary vasculature Thromb Haemost 81 1999 961 966
19. A. Stojanovic, J.A. Marjanovic, V.M. Brovkovych, X. Peng, N. Hay, and R.A. Skidgel A phosphoinositide 3-kinase-AKT-nitric oxide-cGMP signaling pathway in stimulating platelet secretion and aggregation J Biol Chem 281 2006 16333 16339
20. F.Y. Ali, M.G. Hall, B. Desvergne, T.D. Warner, and J.A. Mitchell PPARbeta/delta agonists modulate platelet function via a mechanism involving PPAR receptors and specific association/repression of PKCalpha - brief report Arterioscler Thromb Vasc Biol 29 2009 1871 1873
21. N. Fakhrudin, A. Ladurner, A.G. Atanasov, E.H. Heiss, L. Baumgartner, and P. Markt Computer-aided discovery, validation, and mechanistic characterization of novel neolignan activators of peroxisome proliferator-activated receptor gamma Mol Pharmacol 77 2010 559 566
22. D.M. Ray, S.L. Spinelli, S.J. Pollock, T.I. Murant, J.J. O'Brien, and N. Blumberg Peroxisome proliferator-activated receptor gamma and retinoid X receptor transcription factors are released from activated human platelets and shed in microparticles Thromb Haemost 99 2008 86 95
23. A. Aszodi, A. Pfeifer, M. Ahmad, M. Glauner, X.H. Zhou, and L. Ny The vasodilator-stimulated phosphoprotein (VASP) is involved in cGMP- and cAMP-mediated inhibition of agonist-induced platelet aggregation, but is dispensable for smooth muscle function EMBO J 18 1999 37 48
24. L.J. McDonald, and F. Murad Nitric oxide and cyclic GMP signaling Proc Soc Exp Biol Med 211 1996 1 6
25. C. Liang, Y. Ren, H. Tan, Z. He, Q. Jiang, and J. Wu Rosiglitazone via upregulation of Akt/eNOS pathways attenuates dysfunction of endothelial progenitor cells, induced by advanced glycation end products Br J Pharmacol 158 2009 1865 1873
26. R. Jimenez, M. Sanchez, M.J. Zarzuelo, M. Romero, A.M. Quintela, and R. Lopez-Sepulveda Endothelium-dependent vasodilator effects of peroxisome proliferator-activated receptor beta agonists via the phosphatidyl-inositol-3 kinase-Akt pathway J Pharmacol Exp Ther 332 2010 554 561
27. O. Konopatskaya, K. Gilio, M.T. Harper, Y. Zhao, J.M. Cosemans, and Z.A. Karim PKCalpha regulates platelet granule secretion and thrombus formation in mice J Clin Invest 119 2009 399 407
28. Z. Liu, X. Zhang, W. Cui, X. Zhang, N. Li, and J. Chen Evaluation of short-term and subchronic toxicity of magnolia bark extract in rats Regul Toxicol Pharmacol 49 2007 160 171
29. U.R. Schwarz, U. Walter, and M. Eigenthaler Taming platelets with cyclic nucleotides Biochem Pharmacol 62 2001 1153 1161
30. 3R-associated cGMP kinase substrate determines inositol 1,4,5-trisphosphate receptor susceptibility to phosphoregulation by cyclic nucleotide-dependent kinases J Biol Chem 285 2010 37927 37938
31. M. Antl, M.L. von Bruhl, C. Eiglsperger, M. Werner, I. Konrad, and T. Kocher IRAG mediates NO/cGMP-dependent inhibition of platelet aggregation and thrombus formation Blood 109 2007 552 559